Program

6:30 AM-7:55 AM

Complimentary Continental Breakfast Provided

7:55 AM-9 :00 AM

Welcome and General Session 7: Exploiting Viruses for Cancer Therapy

 

Howard L. Kaufman, MD—Chair
Rutgers Cancer Institute of New Jersey

 

Graham P. Pawelec, PhD—Chair
Universitätsklinikum Tübingen

 

Mary L. (Nora) Disis, MD
University of Washington

Welcome

 

Stephen J. Russell, MD, PhD
Mayo Clinic

Viral Therapy

 

H. Kim Lyerly, MD
Duke University School of Medicine

Viral Vectors for Cancer Vaccines

 

John C. Bell, PhD
Ottawa Hospital Research Institute

Oncolytic Virus Vaccines

 

Panel Question and Answer

9:00 AM-9:45 AM

Keynote Lecture

 

Laurence Zitvogel, MD, PhD
Institut Gustave Roussy

Microbiome and Cancer Immunity

9:45 AM-10:15 AM Break
10:15 AM-11:30 AM

Oral Abstract Session C

James L. Gulley, MD, PhD - Co-Chair

National Cancer Institute at the National Institutes of Health

Ann W. Silk, MD - Co-Chair

Rutgers Cancer Institute of New Jersey

 

Abstract 111: Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.

First author: Holger Lode

 

Abstract 79: CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.

First author: Limo Chen

 

Discussion: Graham P. Pawelec, PhD

Universitätsklinikum Tübingen

 

Abstract 80: Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

First author: Howard Kaufman

 

Abstract 5: Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).

First author: Robert Ferris

 

Discussion: Ezra E.W. Cohen, MD

University of California, San Diego

 

Panel Question and Answer

11:45 AM-1:00 PM

Networking Roundtables: Where Does Immunotherapy Fit in Your Practice?

 

Expert faculty willl lead small-group discussions on lymphoma, lung cancer, ovarian cancer, gastric cancers, bladder cancer, myeloma, breast cancer, and pancreas and liver cancers.

 

For a list of the faculty participants, please visit Networking Opportunities.

11:30 AM-1:00 PM

Complimentary Boxed Lunch Provided

1:00 PM-2:15 PM

General Session 8: Resistance to Immunotherapy

 

James L. Gulley, MD, PhD—Chair
National Cancer Institute at the National Institutes of Health

 

Roger Lo, MD, PhD
University of California, Los Angeles

Melanoma Therapeutic Resistance: Interface between Mutation and Checkpoint Targeted Therapies

 

Katerina A. Politi, PhD
Yale School of Medicine

Rebiopsies in Lung Cancer with Resistance to Immunotherapy

 

Jennifer A. Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center

Mechanisms of Resistance to Immunotherapy in Melanoma

 

Panel Question and Answer

2:15 PM-2:45 PM Break
2:45 PM-4:00 PM

General Session 9: The Most Promising Therapeutic Combinations with Immune Checkpoints

 

Roy S. Herbst, MD, PhD—Chair
Yale University School of Medicine

 

Igor Puzanov, MD, MSCI, FACP
Roswell Park Cancer Institute

Combination Immunotherapy  with T-VEC

 

Robert L. Ferris, MD, PhD
University of Pittsburgh Cancer Institute

Checkpoint Targeting Beyond PD-1 to Overcome Therapeutic Escape: Is There Cross Talk?

 

Lawrence Fong, MD
University of California, San Francisco

How Do Immunotherapy Combinations All Work Together?

 

Roy S. Herbst, MD, PhD
Yale University School of Medicine

Promising Combinations in Lung Cancer with Immune Checkpoints

 

Panel Question and Answer